Michael Matson's questions to Neogenomics Inc (NEO) leadership • Q1 2025
Question
Michael Matson of Needham & Company asked CEO Tony Zook about his comments on M&A and whether to expect an increase in activity. He also questioned if the annual guidance, which was maintained despite increased non-clinical headwinds, suggests that results might land at the lower end of the range.
Answer
CEO Anthony Zook confirmed that NeoGenomics will continue to seek value-generating, accretive tuck-in and licensing opportunities that leverage its strength in community oncology, without being transformational. CFO Jeff Sherman responded that the provided guidance range is reasonable and achievable, noting that the company's forecasting accuracy has improved and that recent performance has often been above the top end of guidance.